Literature DB >> 20559999

Exercise in hypertrophic cardiomyopathy.

Sharlene M Day1.   

Abstract

The risk of sudden cardiac death (SCD) associated with vigorous athletic competition in individuals with hypertrophic cardiomyopathy (HCM) is well documented, and is the basis for recommended exclusion from competitive sports independent of other risk factors. Although SCD risk with recreational exercise is less well defined, published guidelines for participation in recreational sports, based on a consensus of expert opinion, offer a valuable framework for counseling patients. Exercise stress testing is an important diagnostic and prognostic tool in the evaluation of HCM patients, providing an objective measure of functional capacity, physiologic hemodynamic responses to stress, presence of ischemia, and provocable left ventricular outflow tract obstruction. The value of cardiopulmonary exercise testing in HCM is less well studied than in the heart failure population, but can be used to set a safe target for exercise intensity as part of an individualized exercise prescription. The long-term effects of exercise on HCM pathophysiology are largely theoretical at this stage. Potential harmful effects of fatiguing exercise include prolonged contractile dysfunction resulting from microvascular ischemia and energetic compromise. Conversely, several animal studies have shown that voluntary exercise prevents or reverses many pathologic features of HCM, including those related to apoptosis and energetics. Substantial evidence for health-promoting benefits of exercise in the general population, in addition to promising safety and efficacy data in patients with chronic heart failure, emphasizes the need to attain a reasonable balance between potential risks and benefits of aerobic fitness in individuals with HCM.

Entities:  

Mesh:

Year:  2009        PMID: 20559999     DOI: 10.1007/s12265-009-9134-5

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   4.132


  54 in total

1.  Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity).

Authors:  Paul D Thompson; David Buchner; Ileana L Pina; Gary J Balady; Mark A Williams; Bess H Marcus; Kathy Berra; Steven N Blair; Fernando Costa; Barry Franklin; Gerald F Fletcher; Neil F Gordon; Russell R Pate; Beatriz L Rodriguez; Antronette K Yancey; Nanette K Wenger
Journal:  Circulation       Date:  2003-06-24       Impact factor: 29.690

2.  Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation.

Authors:  Barry J Maron; Paul D Thompson; Michael J Ackerman; Gary Balady; Stuart Berger; David Cohen; Robert Dimeff; Pamela S Douglas; David W Glover; Adolph M Hutter; Michael D Krauss; Martin S Maron; Matthew J Mitten; William O Roberts; James C Puffer
Journal:  Circulation       Date:  2007-03-12       Impact factor: 29.690

3.  Clinical characteristics and outcomes of patients with hypertrophic cardiomyopathy with latent obstruction.

Authors:  Joseph C Vaglio; Steve R Ommen; Rick A Nishimura; A Jamil Tajik; Bernard J Gersh
Journal:  Am Heart J       Date:  2008-06-06       Impact factor: 4.749

4.  Exercise-induced systolic dysfunction in patients with non-obstructive hypertrophic cardiomyopathy and mutations in the cardiac troponin genes.

Authors:  K Sakata; H Ino; N Fujino; M Nagata; K Uchiyama; K Hayashi; T Konno; M Inoue; H Kato; Y Sakamoto; T Tsubokawa; M Yamagishi
Journal:  Heart       Date:  2008-10       Impact factor: 5.994

5.  Abnormal cardiac response to exercise in a murine model of familial hypertrophic cardiomyopathy.

Authors:  Lan Nguyen; Jessica Chung; Lien Lam; Tatiana Tsoutsman; Christopher Semsarian
Journal:  Int J Cardiol       Date:  2006-10-24       Impact factor: 4.164

6.  Clinical, hemodynamic, and cardiopulmonary exercise test determinants of survival in patients referred for evaluation of heart failure.

Authors:  J Myers; L Gullestad; R Vagelos; D Do; D Bellin; H Ross; M B Fowler
Journal:  Ann Intern Med       Date:  1998-08-15       Impact factor: 25.391

7.  Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy.

Authors:  Franco Cecchi; Iacopo Olivotto; Roberto Gistri; Roberto Lorenzoni; Giampaolo Chiriatti; Paolo G Camici
Journal:  N Engl J Med       Date:  2003-09-11       Impact factor: 91.245

8.  Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006.

Authors:  Barry J Maron; Joseph J Doerer; Tammy S Haas; David M Tierney; Frederick O Mueller
Journal:  Circulation       Date:  2009-02-16       Impact factor: 29.690

Review 9.  Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases.

Authors:  Barry J Maron; Bernard R Chaitman; Michael J Ackerman; Antonio Bayés de Luna; Domenico Corrado; Jane E Crosson; Barbara J Deal; David J Driscoll; N A Mark Estes; Claudio Gil S Araújo; David H Liang; Matthew J Mitten; Robert J Myerburg; Antonio Pelliccia; Paul D Thompson; Jeffrey A Towbin; Steven P Van Camp
Journal:  Circulation       Date:  2004-06-08       Impact factor: 29.690

10.  Cardiopulmonary responses to exercise in patients with hypertrophic cardiomyopathy.

Authors:  S Jones; P M Elliott; S Sharma; W J McKenna; B J Whipp
Journal:  Heart       Date:  1998-07       Impact factor: 5.994

View more
  4 in total

Review 1.  Prevalence and spectrum diseases predisposing to sudden cardiac death: are they the same for both the athlete and the nonathlete?

Authors:  Anjan S Batra; Seshadri Balaji
Journal:  Pediatr Cardiol       Date:  2012-03       Impact factor: 1.655

Review 2.  Hypertrophic cardiomyopathy: genetics and clinical perspectives.

Authors:  Cordula Maria Wolf
Journal:  Cardiovasc Diagn Ther       Date:  2019-10

3.  Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathy.

Authors:  Jennifer E Ho; Ling Shi; Sharlene M Day; Steven D Colan; Mark W Russell; Jeffrey A Towbin; Mark V Sherrid; Charles E Canter; John Lynn Jefferies; Anne Murphy; Matthew Taylor; Luisa Mestroni; Allison L Cirino; Lynn A Sleeper; Peter Jarolim; Begoña Lopez; Arantxa Gonzalez; Javier Diez; E John Orav; Carolyn Y Ho
Journal:  Open Heart       Date:  2017-11-01

Review 4.  Hypertrophic Cardiomyopathy: Updates Through the Lens of Sports Cardiology.

Authors:  Bradley S Lander; Dermot M Phelan; Matthew W Martinez; Elizabeth H Dineen
Journal:  Curr Treat Options Cardiovasc Med       Date:  2021-05-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.